Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis

Current Rheumatology Reports

Volumn 9, Issue 1, 2007, Pages 78-84

  Compston, Juliet E ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCITONIN; CALCITRIOL; CALCIUM; CLODRONIC ACID; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; METHOTREXATE; PAMIDRONIC ACID; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VITAMIN D;

ARTICLE; AWARENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSENSUS DEVELOPMENT; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; FRACTURE; GLUCOCORTICOID INDUCED OSTEOPOROSIS; HEALTH CARE; HEALTH PROGRAM; HIGH RISK PATIENT; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MORBIDITY; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; SPINE FRACTURE; TREATMENT OUTCOME; VERTEBRA FRACTURE;

BONE DENSITY; CALCIUM; CLINICAL TRIALS; DIPHOSPHONATES; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; PRACTICE GUIDELINES; RISK FACTORS; VITAMIN D;

EID: 34249327777     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-007-0026-x     Document Type: Article

References (49)

1. van Staa TP, Leufkens HG, Abenhaim L, et al.: Use of oral corticosteroids in the United Kingdom. QJM 2000, 93:105-111.
2. Hooyman JR, Melton LJ, Nelson AM, et al.: Fractures after rheumatoid arthritis. A population-based study. Arthritis Rheum 1984, 27:1353-1361.
3. van Staa TP, Leufkens HG, Abenhaim L, et al.: Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15:993-1000.
4. Steinbuch M, Youket TE, Cohen S: Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 2004, 15:323-328.
5. Mazziotti G, Angeli A, Bilezikian JP, et al.: Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 2006, 17:144-149.
6. van Staa TP, Leufkens HG, Abenhaim L, et al.: Oral cortico-steroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000, 39:1383-1389.
7. van Staa TP, Dennison EM, Leufkens HG, Cooper C: Epidemiology of fractures in England and Wales. Bone 2001, 29:517-522.
8. Ip M, Lam K, Yam L, et al.: Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest 1994, 105:1722-1727.
9. Toogood JH, Baskerville JC, Markov AE, et al.: Bone-mineral density and the risk of fracture in patients receiving long-term inhaled steroid-therapy for asthma. J Allergy Clin Immunol 1995, 96:157-166.
10. Wong CA, Walsh LJ, Smith CJ, et al.: Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet 2000, 355:1399-1403.
11. van Staa T, Leufkens HG, Cooper C: Use of inhaled corticosteroids and risk of fractures. J. Bone Miner Res 2001, 16:581-588.
12. van Staa TP, Bishop N, Leufkens HG, Cooper C: Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos Int 2004, 15:785-791.
13. Curtis JR, Westfall AO, Allison JJ, et al.: Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum 2005, 52:2485-2494.
14. Feldstein AC, Elmer PJ, Nichols GA, Herson M: Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos Int 2005, 16:2168-2174.
15. Blalock SJ, Norton LL, Patel RA, Dooley MA: Patient knowledge, beliefs, and behaviour concerning the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2005, 53:732-739.
16. • Newman ED, Matzko CK, Olenginski TP, et al.: Glucocorticoid- induced osteoporosis (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int 2006, 17:1428-1434. This paper is the first to demonstrate that the management of glucocorticoid-induced osteoporosis can be significantly improved by implementation of an organized program of care.
17. Kanis JA: Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002, 359:1929-1936.
18. •• Kanis JA, Johansson H, Oden A, et al.: A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004, 19:893-899. This paper describes the effect of glucocorticoid use on fracture risk in a number of large population-based cohorts and demonstrates its partial independence from bone mineral density.
19. Homik J, Cranney A, Shea B, et al.: Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev 2000, (2):CD001347.
20. Adachi JD, Saag KG, Delmas PD, et al.: Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001, 44:202-211.
21. Adachi JD, Bensen WG, Brown J, et al.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. New Engl J Med 1997, 337:382-387.
22. Cohen S, Levy RM, Keller M, et al.: Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 1999, 42:2309-2318.
23. Herrala J, Puolijoki H, Impivaara O, et al.: Bone mineral density in asthmatic women on high dose inhaled beclomethasone dipropionate. Bone 1994, 15:621-624.
24. Reid IR, Heap SW, King AR, Ibbertson HK: Two-year follow-up of biphosphonate (APD) treatment in steroid osteoporosis. Lancet 1988, 2:1144.
25. Ringe JD, Dorst A, Faber H, et al.: Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003, 14:801-807.
26. Cranney A, Welch V, Adachi JD, et al.: Calcitonin for preventing and treating corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000, (2):CD001983.
27. Lane NE, Sanchez S, Modin GW, et al.: Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled trial. J Clin Invest 1998, 102:1627-1633.
28. Lane NE, Sanchez S, Modin GW, et al.: Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000, 15:944-951.
29. Homik J, Suarez-Almazor ME, Shea B, et al.: Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2002, (2):CD000952.
30. Dykman R, Haralson KM, Gluck OS, et al.: Effect of oral 1,25-dhydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984, 27:1336-1343.
31. Sambrook P, Birmingham J, Kelly P, et al.: Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. New Engl J Med 1993, 328:1747-1752.
32. Lambrinoudaki A, Chan DTM, Lau CS, et al.: Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy: a randomised, double-blind, placebo controlled study. J Rheumatol 2000, 27:1759-1765.
33. Sambrook P, Henderson NK, Keogh A, et al.: Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 2000, 15:1818-1824.
34. Diamond T, McGuigan I, Schonell M, et al.: A 2 year open randomised controlled trial comparing calcitriol to cyclical etidronate for the treatment of glucocorticoid-induced osteoporosis. J Bone Miner Res 1997, 12:S311.
35. Stempfle HU, Werner C, Echtler S, et al.: Prevention of osteoporosis after cardiac transplantation. Transplantation 1999, 68:523-530.
36. Reginster JY, Kuntz D, Verdickt W et al.: Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999, 9:75-81.
37. Lakatos P, Nagy Z, Kiss L, et al.: Prevention of corticosteroid- induced osteoporosis by alfacalcidol. Z Rheumatol 2000, 59(Suppl 1):48-52.
38. Ringe JD, Cöster A, Meng T, et al.: Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcif Tissue Int 1999, 65:337-340.
39. Ringe JD, Faber H, Fahramand P, Schacht E: Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis. J Rheumatol 2005, 76(Suppl):33-40.
40. Sambrook PN, Kotowitz M, Nash P, et al.: Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium. J Bone Miner Res 2003, 18:919-924.
41. de Nijs RN, Jacobs JW, Lems WF, et al.: Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006, 355:675-684.
42. American College of Rheumatology ad hoc Committee on Glucocorticoid-induced Osteoporosis: Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001, 44:1496-1503.
43. Guidelines Working Group for the Bone and Tooth Society, National Osteoporosis Society and Royal College of Physicians 2002: Glucocorticoid- induced osteoporosis: guidelines for prevention and treatment. London: Royal College of Physicians; 2002.
44. Brown JP, Josse RG, Scientific Advisory Council of the Osteoporosis Society of Canada: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002, 167(10 Suppl):S1-34.
45. Nawata H, Soen S, Takayanagi R, et al.: Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society of Bone and Mineral Research. J Bone Miner Metab 2005, 23:105-109.
46. Geusens PP, Lems WF, Verhaar HJ, et al.: Review and evaluation of the Dutch guidelines for osteoporosis. J Eval Clin Pract 2006, 12:539-548.
47. Devogelaer JP, Goemaere S, Boonen S, et al.: Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2006, 17:8-19.
48. • Pennisi P, Trombetti A, Rizzoli R: Glucocorticoid-induced osteoporosis and its treatment. Clin Orthop Relat Res 2006, 443:39-47. This is an excellent up-to-date review of the pathogenesis and management of glucocorticoid-induced osteoporosis.
49. • Curtis JR, Westfall AO, Allison JJ, et al.: Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 2006, 17:1268-1274. This study documents the poor compliance and persistence with bisphosphonate therapy in glucocorticoid users and identifies some of the risk factors responsible.